Archived explainer. For the current picture see today's RDY page.
DR REDDYS LABS LTD ADR (RDY) is down -9.39% in the latest session. Our newswire has captured 8 stories on RDY across 2 sources in the last 36 hours, with AI sentiment reading mixed (avg 52/100).
Dr. Reddy’s Laboratories Ltd (RDY) fell 9.39% to $11.38 in a session marked by a sharp reaction to mixed Q1 FY2027 results and external headwinds. The stock declined after the company reported earnings and revenue below expectations, with additional pressure from political developments threatening new tariffs on generic drugs. The earnings call highlighted challenges in the U.S. market and delays in launching key products like semaglutide.
Dr. Reddy’s Laboratories released Q1 FY2027 results that showed a GAAP EPS of $0.06, missing the $0.17 estimate, and revenue of $853 million, falling short of the $925.53 million forecast. The company also announced a 5.5% year-over-year revenue decline and a profit plunge. During the earnings call, executives noted that launching generic semaglutide tablets in the U.S. is not currently practical due to the tariff environment. The company is working to resume supplies and hopes to bring semaglutide to market by November. These developments, combined with the broader political risk of Trump-era tariff threats, contributed to the sharp sell-off.
RDY has a market cap of $10.5 billion and a P/E ratio of 23.1. Despite a 3.2% revenue increase in the trailing twelve months, the stock has underperformed, trading below its 52-week high of $15.67 and near its 52-week low of $12.19. The stock’s beta of 0.26 suggests it is less volatile than the market, but the recent move indicates heightened sensitivity to sector-specific risks. Short-term sentiment has improved slightly, with a 7-day average of 52 out of 100 compared to a 30-day average of 46. However, the sharp drop suggests market skepticism about the company’s near-term outlook.
The company’s next key event is its scheduled earnings release on July 22, 2026. Investors will be watching for further updates on semaglutide progress and how the company navigates the evolving regulatory and tariff landscape.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Not financial advice.
Dr. Reddy’s Laboratories Ltd (($RDY)) has held its Q1 earnings call. Read on for the main highlights of the call. Dr. Reddy’s Laboratories’ latest earnings call str...
Dr. Reddy's Laboratories Limited (RDY) Q1 2027 Earnings Call July 22, 2026 10:00 AM EDTCompany ParticipantsMannam Venkatanarasimham - CFO & Member of...
An update from Dr Reddy’s Laboratories ( ($RDY) ) is now available. Dr. Reddy’s Laboratories released its unaudited condensed consolidated interim financial stateme...
Dr Reddy’s Laboratories ( ($RDY) ) just unveiled an announcement. On July 22, 2026, Dr. Reddy’s Laboratories disclosed that its Board had approved unaudited consoli...
Dr. Reddy’s Laboratories (RDY) stock falls after weak Q1 FY27 results amid Trump’s tariff threat targeting the generic drugs. Read more here.
Dr. Reddy's press release (RDY): Q1 GAAP EPS of $0.06. Revenue of $853M (-5.5% Y/Y) beats by $7.59M. Operating Working Capital: As on 30th June 2026 at ₹143.5 billion. Capital Expenditu
Dr Reddy’s Laboratories ( ($RDY) ) has issued an announcement. Dr. Reddy’s Laboratories has filed a Form 6-K with the U.S. Securities and Exchange Commission dated ...
Dr Reddy’s Laboratories ( ($RDY) ) just unveiled an update. On July 22, 2026, Dr. Reddy’s Board approved the appointment of biopharmaceutical veteran Dr. Sridevi Kh...
More on RDY: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.
Earlier RDY move explainers: 2026-07-23 · 2026-07-22